The b-catenin-dependent Wnt signaling pathway has key roles in embryonic development and adult tissues and is defective in various cancers. Recent studies highlight the function of two transmembrane RING finger ubiquitin ligases in modulating Wnt signaling and reveal roles for mutations in the RING finger proteins in cancer.
Cancers often harbor defects in evolutionarily conserved pathways that regulate embryonic development, cell-fate specification and homeostasis in adult tissues. The Wnt pathway is a classic example of this phenomenon. The cysteine-rich Wnt proteins are roughly 40 kDa secreted molecules, and Wnts function as close-range signals for their context-specific effects on varied cell phenotypes [1, 2] . The actions of Wnts on target cells include changes in gene expression, cell polarization and directed migration via engagement of distinct downstream effector molecules [1] . For the 'canonical' (b-catenin-dependent) Wnt pathway, Wnts bind to a receptor complex, composed of low-density lipoprotein-related protein 5 or 6 (LRP5/6) and Frizzled (Fz). LRP5/6 have a single membrane-spanning domain, and Fz proteins are seven-transmembrane molecules. There is a high level of complexity in Wnt-Fz interactions, with 19 Wnt and 10 Fz molecules [2] . In the absence of activating Wnt signals at the cell surface, free b-catenin is bound to the 'destruction complex', consisting of glycogen synthase kinase (GSK) 3b, Axin and adenomatous polyposis coli (APC) tumor suppressor proteins, and other factors. This complex phosphorylates b-catenin in its amino-terminal domain. The phosphorylated b-catenin is ubiquitinated, and then degraded by the proteasome. Wnt-mediated activation of the Fz-LRP5/6 complex inhibits b-catenin degradation by preventing b-catenin ubiquitination, allowing newly synthesized b-catenin protein to accumulate in the cell [2, 3] (Figure 1 ). In the nucleus, b-catenin can bind to T cell factor (TCF) transcription factors along with other proteins, and the b-catenin-TCF complexes modulate transcription of selected genes with roles in cell fate, proliferation, and other processes [1, 2] .
Mutations in the b-catenin-dependent Wnt signaling pathway contribute especially to colorectal cancer. About 90% of colorectal cancers have somatic mutations affecting certain canonical Wnt pathway factors [4, 5] . More than 50% of hepatocellular carcinomas have mutations in the canonical Wnt pathway [6] , as do significant subsets of other cancer types [1, 2, 7] . Wnt pathway mutations include inactivation of the APC protein in most colorectal cancers [1, 2, 4, 5] or the AXIN1 protein in some hepatocellular carcinomas [6] , or activating (oncogenic) mutations in key phosphorylation sites in b-catenin's amino-terminal domain in hepatocellular carcinomas and other cancer types [1, 2, 7] . A major consequence of the mutations is that b-catenin is constitutively stabilized in the absence of Wnt signals, consequently altering the transcription of b-catenin-TCF-regulated genes.
Several secreted and transmembrane proteins modulate Wnt-ligand signaling through the Fz-LRP5/6 receptor. Inhibitors that bind to Wnt ligands include secreted Frizzled-related proteins (sFRPs) and the secreted Wnt inhibitory factor 1 (WIF1) [2] . The Dickkopf (DKK) and Sclerostin (SOST) secreted proteins interfere with Wnt-simulated Fz-LRP5/6 interactions, and the APCDD1 (APC down-regulated 1) transmembrane protein interferes with Wnt binding to LRP5/6 [2] . Two distinct protein families function through the Fz-LRP5/6 complex to enhance Wnt signaling. Norrin binds directly to certain Fz proteins (such as Fz4) to activate canonical Wnt signaling independent of Wnts [2] . In contrast, the four R-spondin proteins are secreted, vertebrate-specific factors that enhance signaling via Fz-LRP5/6 complexes, but only in the presence of Wnt ligands [2] .
Until recently, a major unresolved issue was how R-spondins enhanced Wnt ligand-dependent signaling. The first clues were provided by demonstrations that R-spondins bind to one of three leucine-rich, G-protein-coupled receptors (Lgr4/5/6) [8] [9] [10] . Lgr4/5/6 are seven-transmembrane receptors with similarity to the G-protein-coupled hormone receptors, such as the receptor for thyroid-stimulating hormone [2, 11] . Prior efforts had shown Lgr5 gene expression was activated by Wnt-b-catenin-TCF-dependent signaling [2, 11] . More significantly, Lgr5 was a high fidelity biomarker of Wnt-dependent crypt base columnar intestinal stem cells in vivo, and single intestinal Lgr5-expressing cells gave rise to 'organoids' in vitro [12] . Lgr5 and Lgr6 mark stem cells in other tissues [11] , whereas Lgr4 is more broadly expressed and not likely to be stem cell specific [11] . The finding that R-spondins bind to Lgr family members was obviously intriguing. However, the mechanisms by which the R-spondin-Lgr4/5/6 interactions might enhance Wnt signaling through the Fz-LRP5/6 co-receptor complex remained unclear. Two recent papers in Nature have now provided powerful insights into how R-spondins likely enhance Wnt signaling [13, 14] , and the findings have important implications for the cancer field.
Both papers took advantage of gene expression profiling as a starting point. Prior efforts had demonstrated that multiple proteins encoded by genes activated by b-catenin-TCF functioned as negative feedback regulators of Wnt signaling, including AXIN2, DKK1, NKD1, APCDD1, and WIF1 [1, 2] . Hao et al. [13] sought to define genes whose expression was tightly correlated with AXIN2 expression and that might also regulate the Wnt pathway. The expression of genes encoding two closely related transmembrane RING (TM-RING) finger proteins with E3 ubiquitin ligase function, known as ZNRF3 and RNF43, was linked to b-catein function and largely paralleled that of AXIN2, including in colorectal cancers [13] . The same two genes drew the attention of Koo et al. [14] in their analysis of genes expressed in Lgr5-expressing crypt base columnar cells. The two papers diverge in terms of the specific approaches and models used to explore ZNRF3 and RNF43 function. However, both papers arrive at similar conclusions; namely, that ZNRF3 and RNF43 regulate the stability and levels of cell-surface Fz and LRP5/6 proteins via ubiquitination and then internalization and lysomal degradation of the receptor components. Both groups propose that ZNRF3 and RNF43 function, akin to AXIN2 and some other Wnt targets, as negative feedback regulators of Wnt signaling.
The paper from Hao et al. [13] also provides data indicating that R-spondins function to stabilize Wnt receptor levels on the cell surface through the interaction of an Lgr family member and a ZNFR3/RNF43 member with R-spondins. R-spondin binding to this Lgr-TM-RING receptor complex leads to the clearance of the TM-RING protein from the membrane (presumably via lysosomal degradation of the complex), with resultant increased levels of the Fz-LRP5/6 receptor complex and enhanced Wnt signaling [13] (Figure 2 ). The paper from Koo et al. [14] explores the roles of RNF43 and ZNRF3 as presumptive tumor suppressor proteins, demonstrating that conditional inactivation of both Rnf43 and Znrf3 in murine intestinal epithelium led to marked expansion of the proliferative zone of the crypt and the formation of epithelial tumors. The tumors resembled intestinal adenomas and were composed chiefly of cells found at the base of normal intestinal crypts, namely, crypt base columnar cells (expressing Lgr5 and other stem-cell markers) and Paneth cells [14] . Paneth cells are a specialized cell type at the crypt base in normal small intestine that have a role in maintaining the stem-cell niche by supplying Wnt ligands and other signals to crypt base columnar cells. Using intestinal organoids generated from Rnf43/Znrf3 double-deficient epithelial cells, Koo et al. [14] demonstrated that the mutant organoids no longer required R-spondin1 supplementation, but were highly dependent on locallly supplied Wnts, such as Paneth-cell-derived Wnt3a.
Hao et al. [13] noted that RNF43 inactivating mutations were found in some pancreatic tumors [15, 16] , and Koo et al. [14] noted that two colorectal cancer cell lines with activating b-catenin mutations (and not APC inactivation) had inactivating RNF43 mutations [17] . In the HCT116 colorectal cancer cell line with b-catenin and RNF43 defects, Koo et al. [14] showed that RNF43 inactvation may allow Wnt ligands to enhance b-catenin-TCF signaling beyond that achieved by a b-catenin mutation alone. RNF43 is inactivated in various cancers, and in a recent study 10% of bile duct cancers were reported to have RNF43 mutations [18] . Some prior published results may also be clarified by the findings in these Nature papers. The Aaronson group had previously reported that b-catenin-TCF signaling in the HCT116 colorectal cancer cell line was dependent on Wnt ligand [19] , and their group recently reported that LRP5/6 proteins are overexpressed in some sarcomas in the absence of demonstrable defects in the genes encoding LRP5/6 [20] . Increased LRP5/6 protein levels in these studies could be due in some cases to inactivation of RNF43 and/or ZNRF3.
Whether RNF43 and ZNRF3 negatively regulate all or nearly all Fz-LRP5/6 co-receptor complexes or only a subset is uncertain. The identities of other proteins that might be regulated by RNF43/ZNRF3 is also unknown. Whether all R-spondin-Lgr interactions can remove the TM-RING complex from the cell surface remains to be determined. Cell context and variable expression patterns for RNF43 and ZNRF3 might offer some explanation for why combined somatic Left: In the absence of an activating Wnt ligand, b-catenin is phosphorylated at multiple serine/ threonine residues in its amino-terminal domain by the 'destruction complex', consisting of Axin, APC, GSK3b, and casein kinase 1a (CK1a). The amino-terminally phosphorylated b-catenin is recognized by a ubiquitin ligation complex that contains bTrCP, and the ubiquitinated b-catenin is degraded by the proteasome. The ubquitination and degradation of b-catenin allows the destruction complex to bind and phosphorylate additional b-catenin molecules. Right: In the presence of an activating Wnt ligand, which bridges the Fz-LRP5/6 proteins and brings about phosphorylation of cytoplasmic LRP5/6 sequences by CK1a, the destruction complex is recruited to the phosphorylated cytoplasmic domain of LRP5/6. While the destruction complex can still bind and phosphorylate b-catenin, ubiquitination by bTrCP is blocked, allowing newly synthesized b-catenin to accumulate in the cell and activate transcription in the nucleus, via interactions with TCF proteins and various co-factors, including the p300/CBP histone acetyltransferases, BCL9, and Pygopus (Pygo), among others. inactivation of Rnf43 and Znrf3 was required to instigate intestinal tumorigenesis in the mouse, yet only the RNF43 gene seems to be somatically mutated at moderate frequency in human cancers. The basis for why various other negative feedback regulators of the Wnt pathway, such as NKD1, DKK1, and APCDD1, are not recurrently mutated in cancer is not clear, though baseline redundancy for some of their functions in Wnt signaling may be part of the answer. Data addressing some of these issues will likely be forthcoming. Moreover, given the potential opportunities for targeting Wnt signaling in cancers where RNF43 (and/or possibly ZNRF3) are defective, there will likely be considerable enthusiasm for new strategies and reagents to target Wnt ligands and receptors directly in certain subsets of cancer. In the presence R-Spo, the TM-RING protein and Lgr proteins are brought into a complex by R-spo, and the Lgr-R-spo-TM-RING complex is then targeted for lysosomal degradation in an E3 ligase-dependent manner. This potentiates Wnt/b-catenin signaling by reducing Fz and LRP turnover, thus allowing accumulation of Fz-LRP receptors at the cell surface.
